Please assess the completion status of the following clinical trial:

Trial Title: Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer patients who have failed standard therapy for their disease or for whom no such therapy is available are eligible, for which 5-fluoropyrimdines, including 5-FU, or inhibitors of DHFR (dihydrofolate reductase), including pralatrexate, have the potential for therapeutic benefit~* Objectively measurable disease is preferred, but not required~* Performance status of 0-2 (Eastern Cooperative Oncology Group \[ECOG\])~* Prior treatment:~* The patient should have recovered from the toxicities associated with prior chemotherapy (at least 3 weeks from prior therapy)~* At least two or more weeks should have elapsed since any radiotherapy, and the patient should have recovered from the toxicity associated with such therapy~* If a recent surgical procedure has been performed, the patient should have recovered from the surgery prior to entering this trial~* Absolute granulocyte count of 1500 per mcL or greater~* Platelet count of 100,000 per mcL or greater~* Serum bilirubin less than 1.5 times the upper limits of the institutional normal~* Serum creatinine less than the upper limits of normal~* The patient must willingly give signed informed consent~Exclusion Criteria:~* Pregnant women and nursing mothers are ineligible; eligible patients of reproductive potential should use adequate contraception if sexually active~* Serious concurrent medical illness which would jeopardize the ability of the patient to receive the chemotherapy program outlined in this protocol with reasonable safety~* Patients with active infections requiring intravenous antibiotic therapy are not eligible until the infection has resolved~* Patients who are human immunodeficiency virus (HIV) antibody positive and are receiving highly active antiretroviral therapy (HAART) are ineligible~* Concomitant administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and trimethoprim/sulfamethoxazole will not be allowed

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy) (Type: EXPERIMENTAL): Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).